

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

TITAN PHARMACEUTICALS INC

Form 8-K

May 15, 2003

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT 1934

DATE OF REPORT: MAY 15, 2003

TITAN PHARMACEUTICALS, INC.

-----  
(Exact name of registrant as specified in charter)

DELAWARE	0-27436	94-3171940
----- (State or other jurisdiction of incorporation)	----- (Commission File Number)	----- (IRS Employer Identification No.)
400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO, CALIFORNIA		94080
----- (Address of principal executive offices)		----- (Zip Code)
Registrant's telephone number, including area code:	(650) 244-4990	-----

-----  
ITEM 5. OTHER EVENTS

The registrant hereby incorporates by reference the press release dated May 15, 2003 attached hereto as Exhibit 99.1 ("Titan Reports First Quarter 2003 Results").

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits

99.1 Press Release - Titan Reports First Quarter 2003 Results

-----  
2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

TITAN PHARMACEUTICALS, INC.

By: /s/ Robert E. Farrell

-----  
Robert E. Farrell, Executive Vice President  
and Chief Financial Officer

Dated: May 15, 2003

3

-----